Clinical Trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Study acronym: SUNRAY-02
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Protocol Amendment History 3 changes
critical Primary endpoint(s) modified 2026-07-17
notable Trial sites expanded: 361 -> 364 locations 2026-06-19
notable Trial sites expanded: 354 -> 361 locations 2026-06-04
Trial Details
NCT Number NCT06890598
Lead Sponsor Eli Lilly and Company
Collaborators: AstraZeneca
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 700 participants
Start Date 2025-03-27
Primary Completion 2029-05 (estimated)
Study Completion 2032-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-16